This research investigates how melanoma switches between two gene states—one fast-growing and treatable, the other slow but highly invasive and responsible for brain metastases. By identifying genes that control this transition, the study aims to force melanoma into a more treatable form, improving therapeutic options and patient outcomes.

This research engineers immune T cells to better fight ovarian cancer. By modifying them to recognize tumor-specific proteins and resist cancer’s suppressive signals, the project strengthens the body’s natural defenses. The goal is to improve immunotherapy effectiveness, overcome tumor resistance, and increase survival rates for women facing this deadly disease.

This research investigates Large Granular Lymphocyte Leukemia, where protective T cells become cancerous. The project explores how DNA methylation silences normal T-cell function and tests drugs that reverse this process. By removing harmful chemical modifications, the goal is to restore immune cells to their healthy, protective “superhero” role.

Cancer often becomes resistant to treatment due to the protein CDK8, which helps reprogram cancer cells. Traditional inhibitors fail because CDK8 still acts as a structural scaffold. This research develops targeted degraders that use the cell’s recycling system to eliminate CDK8 entirely, preventing resistance and improving future cancer therapies.

This research targets cancer more precisely by focusing on a unique region of the PLK1 protein that drives tumor growth. By designing drugs that bind specifically to this domain using AI and laboratory testing, the approach aims to kill cancer cells while sparing healthy tissue.

Pancreatic ductal adenocarcinoma resists immunotherapy by building an immune-suppressive tumor fortress. This research explores how specific bacteria found in long-term survivors may reshape the tumor microenvironment, enhance immune checkpoint therapy, and help immune cells overcome suppression to attack pancreatic cancer more effectively.

This research isolates and characterizes new flavonoids from Colona leonei with promising anti-cancer properties. These compounds selectively target cancer cells while sparing healthy ones. Upcoming tests will assess their effectiveness on cancer cell lines. The work also highlights preventive benefits of flavonoid-rich foods and frames cancer as a global, personal, and societal challenge.

This project develops an “Aptamer Express,” a DNA-based Trojan horse designed to bypass the brain’s protective barriers, target tumours, and deliver cancer-killing drugs directly to brain cancer cells. The approach aims to overcome treatment resistance, improve precision, and reduce side effects, offering new hope for patients and their families.